ERBB2 and breast cancer: These resistance mechanisms are particularly problematic in aggressive subtypes of breast cancer, such as triple-negative breast cancer (TNBC), which lacks expression of hormone receptors and HER2, making it more difficult to treat with conventional therapies 5.